HMOX1 and breast carcinoma: Inhibition of HMOX1 has been demonstrated to increase the efficacy of chemotherapeutic agents, such as doxorubicin in breast cancer and temozolomide (TMZ) in melanoma, enhancing their therapeutic impact12.